Primary thromboprophylaxis in symptomatic outpatients with COVID-19: no benefit in two randomized trials
Two trials show no differences between patients who received enoxaparin vs standard of care The routine use of antithrombotic therapies to prevent thromboembolic complications provided no benefit for symptomatic outpatients with COVID-19, according to the results of two randomized trials. In the OVID trial, the 30-day risk of hospitalization and death was similar among patients who